Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
CLL Society has created our Statement on Mask Wearing and Other Protective Measures for Those Living with CLL to protect against respiratory infections spread.
Small lymphocytic lymphoma (SLL) is a slow-growing, chronic blood cancer involving an abnormal overgrowth of white blood cells called B-lymphocytes.
Small lymphocytic lymphoma (SLL) is a slow-growing, chronic blood cancer involving an abnormal
overgrowth of white blood cells called B-lymphocytes.
Pirtobrutinib is a new BTK inhibitor that binds differently (non-covalently) to BTK than the three approved BTK inhibitors, ibrutinib, acalabrutinib, and zanubrutinib.
Follow-up results from a phase 1/2 trial of acalabrutinib in CLL / SLL patients further confirm that acalabrutinib is safe & effective.
Starting treatment for CLL / SLL requires a complex decision-making process. There are several well-established choices
We discuss combination therapies for CLL and SLL, focusing on the combination of ibrutinib plus venetoclax.
Final data from a phase 1/2 clinical trial with six years of follow-up show that first-line acalabrutinib produces high response rates and rapid, durable responses in patients with CLL
MS-553, a protein kinase C-beta (PKCß) inhibitor, is an exciting new agent in a yet-to-be-approved class of drugs that target an area of the B-cell receptor pathway independent of Bruton tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCy2) mutations which confer resistance to BTK inhibitors.
One click to our most popular content.
